RESULTS	A significantly smaller proportion of patients treated with gabapentin enacarbil ( 9/96 [ 9 % ] ) experienced relapse compared with the placebo-treated patients ( 22/97 [ 23 % ] ) ( odds ratio , 0.353 ; 95 % confidence interval , 0.2-0 .8 ; P = .02 ) .\